“Hepatitis B virus (HBV) is an oncogenic virus that causes liver cancer at the same rate as someone who actively smokes one pack of cigarette per day. Yet, we wait to treat HBV infected patients until they develop liver disease before initiating treatment. The WHO ‘Best buys’ document provides recommended interventions for the prevention and control of noncommunicable diseases, and recently prevention of liver cancer through hepatitis B immunisation has been included as a recommendation. This panel discussion and Q&A will focus on the integration of the hepatitis community and hepatitis services with liver cancer and NCDs.

Chair:

- Cary James, CEO, World Hepatitis Alliance

Panel:

- Rosie Tasker, Global Advocacy Manager, Union for International Cancer Control (UICC)

- Devin Razavi-Shearer, Associate Director, HBV/HDV, Center for Disease Analysis Foundation”